Support Line: 0800 002 9002
General Enquiries: 01223 870008
  »  Kidney Cancer News  »  Eisai files kidney cancer drug in Europe

Eisai files kidney cancer drug in Europe

by | Jan 13, 2016 | Kidney Cancer News

Eisai has submitted an application to market its oncology drug lenvatinib for the treatment of patients with renal cell carcinoma.
The file is centred on Phase II showing that the drug significantly extended progression-free survival (PFS) when added to treatment with Novartis’ Afinitor (everolimus); those given the combination regimen experienced a median PFS of 14.6 months versus 5.5 months for those taking everolimus alone.
Read the full story HERE on PhamaTimes

<a href="" target="_self">Malcolm Packer</a>

Malcolm Packer

Malcolm is Chief Executive Officer at Kidney Cancer UK and Kidney Cancer Scotland and has worked with the charity in various capacities for over 15 years.